PARAMUS, NJ – March 23, 2022 – (Newswire.com)
Epygenix Therapeutics, a clinical-stage biopharmaceutical company developing drugs for rare and incurable forms of genetic epilepsy, announces the appointment of G. Michael Landis, CPA, as Chief Financial Officer. Mr. Landis is a highly accomplished financial executive who brings over 25 years of expertise in public companies, capital markets transactions, investor relations and financial reporting.
“We are very pleased to have Mike Landis join our team as the new Chief Financial Officer of Epygenix,” said Alex Yang, JD, LLM, Chairman and Executive Director of the Board of Epygenix. “Given his dynamic background, we are confident that Mike will bring significant value to our next phase of growth strategies in commercialization, partnership and drug listing opportunities.”
Prior to joining Epygenix, Mr. Landis was most recently CFO of Avisa Diagnostics Inc., a publicly traded medical device company. While there, he was responsible for strategic and tactical finance initiatives and was directly involved in investor relations and capital raising activities. Previously, he was a senior accountant and treasurer at Lannett Company Inc., a publicly traded pharmaceutical company, where he led acquisitions and related financing activities and was a member of the management team that successfully completed a $1.2 billion acquisition. Mr. Landis has also been actively involved in the initial public offering (IPO) process in previous CFO roles at companies such as Akrion Inc. and AlliedBarton Security Services, LLC. Previously, he worked in various other publicly listed companies after starting his career with the big four accounting firms.
Darren Cline, President and CEO of Epygenix, said, “We are delighted to welcome Mike to Epygenix. He brings the broad financial knowledge and experience needed as we move forward in executing our growth strategy. As a key member of the management team, I look forward to working with him.
“I am very pleased to join Epygenix at this significant stage in the company and to be able to share my financial expertise as it moves into its next phase of clinical development towards future commercialization,” said Mr. Landis. “It is extremely rewarding to be part of a team committed to bringing safe and effective therapies to patients living with rare genetic epilepsies. I am ready to jump in and achieve great things together.
About Epygenix Therapeutics, Inc.
Epygenix Therapeutics, Inc. is a precision medicine-based biopharmaceutical company focused on the discovery and development of drugs to treat rare and incurable forms of childhood genetic epilepsy, such as Dravet syndrome. Epygenix is currently focused on developing the EPX-100, EPX-200, and EPX-300. These drug candidates abolish seizure behavior and electrographic seizure activity and were discovered in a zebrafish Dravet syndrome model that mimics human pathology. For more information, visit www.epygenix.com.
Head of Investor Relations and Director of Business Development
press release department
Epygenix Therapeutics Announces Appointment of G. Michael Landis as Chief Financial Officer